Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 03/16–03/18 | 03/18 | 107,250 sh6 trades | $50.24avg. | $5,388,431.52 | −86.3% | |
Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 03/13 | 03/16 | 35,000 sh3 trades | $50.37avg. | $1,763,124.42 | −3.5% | |
Frederick M. HudsonDirector | Supernus PharmaceuticalsSUPN | Open-market sale | 03/12 | 03/16 | 5,369 sh | $50.61 | $271,725.09 | −8.2% |
Supernus PharmaceuticalsSUPN | Open-market sale | 03/09–03/10 | 03/10 | 8,877 sh2 trades | $54.50avg. | $483,797 | −100.0% | |
Frank MottolaSVP, Chief Tech. Ops. Officer | Supernus PharmaceuticalsSUPN | Open-market sale | 03/09 | 03/10 | 1,623 sh | $53.65 | $87,073.95 | −8.1% |
Supernus PharmaceuticalsSUPN | Open-market sale | 03/05–03/06 | 03/09 | 18,787 sh2 trades | $53.38avg. | $1,002,811 | −40.8% | |
Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 02/19 | 02/23 | 4,475 sh2 trades | $51.01avg. | $228,264.93 | −100.0% | |
Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/12/19 | 25/12/22 | 20,000 sh2 trades | $50.41avg. | $1,008,150 | −56.3% | |
Padmanabh P. BhattSr. VP of IP, CSO | Supernus PharmaceuticalsSUPN | Open-market sale | 25/12/18 | 25/12/19 | 710 sh | $44.44 | $31,552.4 | −4.7% |
Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/10/09 | 25/10/10 | 25,000 sh2 trades | $50.77avg. | $1,269,234 | −19.3% | |
Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/10/09 | 25/10/10 | 59,900 sh2 trades | $50.57avg. | $3,029,336.39 | −4.7% | |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/10/02 | 25/10/03 | 1,904 sh | $48.06 | $91,506.24 | −0.2% |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/10/01 | 25/10/02 | 40,173 sh | $48.07 | $1,931,116.11 | −3.3% |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/09/30 | 25/10/01 | 8,588 sh | $48.25 | $414,371 | −0.7% |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/09/29 | 25/09/30 | 10,235 sh | $48.02 | $491,484.7 | −0.9% |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/09/23 | 25/09/24 | 29,513 sh | $47.23 | $1,393,898.99 | −2.5% |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/09/22 | 25/09/23 | 16,587 sh | $47.02 | $779,920.74 | −1.5% |
Frank MottolaSVP, Chief Tech. Ops. Officer | Supernus PharmaceuticalsSUPN | Open-market sale | 25/09/12 | 25/09/15 | 5,000 sh | $45.87 | $229,350 | −24.4% |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/09/08 | 25/09/09 | 6,322 sh | $46.29 | $292,645.38 | −0.6% |
Jack A. KhattarPresident, CEO | Supernus PharmaceuticalsSUPN | Open-market sale10b5-1 plan | 25/09/05 | 25/09/08 | 55,578 sh | $46.01 | $2,557,143.78 | −4.8% |